Intellia’s delivery address

Intellia Therapeutics Inc. (NASDAQ:NTLA) published data supporting its lead in vivo gene editing program and providing proof of concept for its delivery technology this week. Now, the company wants to see just how far the delivery platform extends.

In Cell Reports, Intellia researchers published a collection of data presented at scientific conferences over the past year showing delivery of CRISPR-Cas9 (CRISPR-associated protein 9)-based therapies using a lipid nanoparticle (LNP) delivery vehicle can help treat transthyretin amyloidosis in mice. ...